Roche's Obesity Drug Shows Strong Diabetes Data, Threatening Amgen and Lilly
AMGN sits 45% above its 52-week low of $269.77.
Summary
Roche's enicepatide delivered 15.5% weight loss and significant HbA1c reduction in a mid-stage trial for obese/overweight patients with type 2 diabetes, with 62% reaching non-diabetic HbA1c levels. This is a direct competitive threat to Amgen's obesity pipeline and Eli Lilly's market leadership. The data strengthens Roche's position in the $100B+ obesity market and raises the bar for Amgen's own candidates. Amgen shares already fell 9% earlier this month on Novartis's cardiovascular failure, and this adds pressure on its obesity program. Watch for Amgen's own obesity data readouts and Roche's planned late-stage trials in H1 2027.
At the time of this announcement, AMGN was trading at $392.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $212.6B. The 52-week trading range was $269.77 to $447.03. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.